Case Report

Hypersexuality Complication of Dopamine Agonists: Pramipexole or Ropinirole?

Volume: 1 Number: 2 September 1, 2021
  • Yaprak Secıl
  • Sehnaz Arıcı
  • Yesim Beckmann
  • Gaye Eryasar
  • Ayse Irem Tenekecıoglu
TR EN

Hypersexuality Complication of Dopamine Agonists: Pramipexole or Ropinirole?

Abstract

Antiparkinsonian drugs especially dopamine agonists have many side effects. Do-pamine agonists have been linked with compulsive inappropriate behaviours such as gambling, compulsive shopping, hobbyism, other repetitive or purposeless behaviors such as punding, compulsive eating and hypersexuality. However pathological hypersexuality has rarely surfaced in routine Parkinson’s disease practice. We present clinical findings of a seventy-three year old male Parkinson’s disease patient with diagnosis of hypersexuality as a side effect of pramipexole. After pramipexole was withdrawn, dopamine agonist was changed to ropinirole and full remission was observed. Prevalence of psychiatric disorders in patients suffering from Parkinson’s disease varies from 12 to 90%. Hypersexuality is a common impulse control disorder seen in Parkinson’s disease and noted in these patients taking a variety of dopaminergic agents; including levodopa, dopamine agonists or MAO inhibitors. In our patient, pramipexole caused hypersexuality unexpectedly. Since this case constitutes interesting findings in two different points, one is hypersexuality with pramipexole, the other is no hypersexuality with use of ropinirole after pramipexole withdrawal, it is chosen to be presented here.

Keywords

Details

Primary Language

English

Subjects

Clinical Sciences

Journal Section

Case Report

Authors

Yaprak Secıl This is me
0000-0002-8283-9680
Türkiye

Sehnaz Arıcı This is me
0000-0001-5079-2681
Türkiye

Yesim Beckmann This is me
0000-0001-5158-8834
Türkiye

Ayse Irem Tenekecıoglu This is me
0000-0002-1166-8204
Türkiye

Publication Date

September 1, 2021

Submission Date

June 17, 2021

Acceptance Date

August 23, 2021

Published in Issue

Year 2021 Volume: 1 Number: 2

APA
Secıl, Y., Arıcı, S., Beckmann, Y., Eryasar, G., & Tenekecıoglu, A. I. (2021). Hypersexuality Complication of Dopamine Agonists: Pramipexole or Ropinirole? Güncel Tıbbi Araştırmaları Dergisi, 1(2), 32-36. https://doi.org/10.52818/cjmrtu.2021.8
AMA
1.Secıl Y, Arıcı S, Beckmann Y, Eryasar G, Tenekecıoglu AI. Hypersexuality Complication of Dopamine Agonists: Pramipexole or Ropinirole? CJMR. 2021;1(2):32-36. doi:10.52818/cjmrtu.2021.8
Chicago
Secıl, Yaprak, Sehnaz Arıcı, Yesim Beckmann, Gaye Eryasar, and Ayse Irem Tenekecıoglu. 2021. “Hypersexuality Complication of Dopamine Agonists: Pramipexole or Ropinirole?”. Güncel Tıbbi Araştırmaları Dergisi 1 (2): 32-36. https://doi.org/10.52818/cjmrtu.2021.8.
EndNote
Secıl Y, Arıcı S, Beckmann Y, Eryasar G, Tenekecıoglu AI (September 1, 2021) Hypersexuality Complication of Dopamine Agonists: Pramipexole or Ropinirole? Güncel Tıbbi Araştırmaları Dergisi 1 2 32–36.
IEEE
[1]Y. Secıl, S. Arıcı, Y. Beckmann, G. Eryasar, and A. I. Tenekecıoglu, “Hypersexuality Complication of Dopamine Agonists: Pramipexole or Ropinirole?”, CJMR, vol. 1, no. 2, pp. 32–36, Sept. 2021, doi: 10.52818/cjmrtu.2021.8.
ISNAD
Secıl, Yaprak - Arıcı, Sehnaz - Beckmann, Yesim - Eryasar, Gaye - Tenekecıoglu, Ayse Irem. “Hypersexuality Complication of Dopamine Agonists: Pramipexole or Ropinirole?”. Güncel Tıbbi Araştırmaları Dergisi 1/2 (September 1, 2021): 32-36. https://doi.org/10.52818/cjmrtu.2021.8.
JAMA
1.Secıl Y, Arıcı S, Beckmann Y, Eryasar G, Tenekecıoglu AI. Hypersexuality Complication of Dopamine Agonists: Pramipexole or Ropinirole? CJMR. 2021;1:32–36.
MLA
Secıl, Yaprak, et al. “Hypersexuality Complication of Dopamine Agonists: Pramipexole or Ropinirole?”. Güncel Tıbbi Araştırmaları Dergisi, vol. 1, no. 2, Sept. 2021, pp. 32-36, doi:10.52818/cjmrtu.2021.8.
Vancouver
1.Yaprak Secıl, Sehnaz Arıcı, Yesim Beckmann, Gaye Eryasar, Ayse Irem Tenekecıoglu. Hypersexuality Complication of Dopamine Agonists: Pramipexole or Ropinirole? CJMR. 2021 Sep. 1;1(2):32-6. doi:10.52818/cjmrtu.2021.8

Cited By